Odyssean LLC Invests $530,000 in Kenvue Inc. $KVUE

Odyssean LLC bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 27,730 shares of the company’s stock, valued at approximately $530,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Johnson Financial Group Inc. acquired a new stake in shares of Kenvue in the 2nd quarter valued at $26,000. CoreCap Advisors LLC grew its stake in shares of Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares in the last quarter. Elyxium Wealth LLC acquired a new position in shares of Kenvue during the fourth quarter worth $26,000. MV Capital Management Inc. purchased a new position in Kenvue in the fourth quarter valued at $28,000. Finally, Bell Investment Advisors Inc purchased a new position in Kenvue in the second quarter valued at $35,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on KVUE shares. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. UBS Group dropped their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Barclays upped their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and an average price target of $19.27.

Kenvue Trading Down 0.5%

NYSE KVUE opened at $19.23 on Thursday. The firm’s fifty day moving average price is $19.12 and its 200 day moving average price is $18.23. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $20.95. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. The company has a market capitalization of $36.94 billion, a price-to-earnings ratio of 22.10, a price-to-earnings-growth ratio of 1.38 and a beta of 0.47.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.97 billion. During the same period last year, the firm earned $0.29 earnings per share. Kenvue’s revenue was up 3.0% on a year-over-year basis. On average, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th were issued a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. The ex-dividend date of this dividend was Wednesday, August 12th. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is presently 96.55%.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.